(8-108) Efficacy Data from ECOSPOR III: A Phase 3, Double-blind, Placebo-controlled, Randomized Trial of SER-109, an Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection
Tuesday, December 6, 2022
2:00 PM – 3:30 PM
Location: Bayside A, Level 1
Category: Evaluative Study Topic: Infectious Diseases/HIV
Co-Author(s): Mark Wilcox, Thomas Louie, Paul Feuerstadt, Lisa von Moltke
